China ADR stock research

Research, Report & Profiling Services
by IPOdesktop.com
Sinovac Biotech (SVA)

Stock symbol: SVA………..……….….…..………..…..………….………Ave volume (3 mos) 5mm
Stock price 10/8/09: $7.08………….……..………..………….Common shares 6/30/09: 42.42mm
52 week Range: $.75 to $12.50….…..……………..………Equity market capitalization: $300mm

Recent News …..Stock Price & Chart …..SEC Filings

MISSION

Supply vaccines to eliminate human diseases.

BUSINESS

· Research, development, commercialization, and sales of human vaccines for infectious illnesses such as Hepatitis A and Hepatitis B, influenza and “SARS”.

· Sinovac is the first and currently the only company in the world to have been granted permission to begin clinical trials for a vaccine to prevent SARS.

· Sinovac is one of the leading emerging biotechnology companies in China.

RECENT DEVELOPMENTS

Obtains second order from Chinese central government for H1N1 Vaccine; 3 million doses, Sept 30 read more

Obtains Lot Release Certificate for Its First Batch of H1N1 Vaccine, Sept 8 read more

Hong Kong Department of Health Visited Sinovac on R&D and Production of H1N1 vaccine, Sept 8 see pictures & read more

Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government, Sept 4 read more

More recent developments

PRODUCTS

Initiated production of the H1N1 vaccine on June 15, 2009 and initiated the clinical trial on July 22. On August 17, Sinovac announced its top-line positive results of the H1N1 vaccine clinical trials, in which the vaccine showed good safety and immunogenicity profiles after one shot. Following the positive results of an experts' evaluation conference organized by the State Food and Drug Administration (SFDA) on September 3, 2009, Sinovac obtained the production license from the SFDA for PANFLU.1, Sinovac's H1N1 vaccine

Healive® - Inactivated Hepatitis A Vaccine

BiliveTM is the first, and currently only, combined inactivated hepatitis A and B vaccine developed by Chinese scientists

Split Influenza Vaccine

STRATEGIC PARTNERS

Peking University – Established in 1898, located in the south of Beijing, Peking University is China’s first national university. Peking University live-science College was once Peking University’s biology department (established in 1925). Currently, 26 teachers and students of the college have become academicians for the Chinese Academy of Science and Engineering. Presently the college has 6 departments, 5 centers, 2 institutes, 2 national laboratories, 2 national bases and 5 national academies. The medicine department of Peking University was established Oct. 26th, 1912 and is the first western medicine national school launched by China. The medicine department of Peking University specializes in teaching, researching and medical care, with 20 core subjects, 1 national laboratory and 10 ministerial laboratories.

Institute of Laboratory Animal Science – is the largest integrated laboratory animal science research institute in China. The institute includes 6 professional laboratories, including: laboratory animal pathology; microbiology; heredity and breeding; environment nutrition; gnotobiotes animals; and engineering technology; as well as 2 breeding farms for rodents and primates. It is an affiliate of Chinese Association of Laboratory Animals and the Laboratory Animal Committee of Health Ministry.

NICPBP (National Institute for the Control of Pharmaceutical and Biological Products) – is a subordinate organization of the State Food and Drug Administration (SFDA). Established in 1950, it is the supreme statutory authority for national pharmaceutical and biological inspection and arbitration. It has a comprehensive national pharmaceutical, biological products and medical instruments quality-inspection institute, with responsibilities for inspection, research, teaching and standardization.

National Institute for Viral Disease Control and Prevention – is a national professional disease control and prevention institute under the lead of Chinese Center for Disease Control and Prevention (China CDC). Its main functions are to: provide scientific basics for public laws, codes, regulations, policies, standards, criterion, counter plans and strategies for viral disease control and prevention. Additionally, it conducts studies on control and measurement strategies; provides the government with accurate, scientific, complete and timely viral disease surveillance; pandemic information and advice; conducts surveys; and responds to severe diseases in field.

National Institute for Infectious Disease Control and Prevention – is a national professional infectious disease control and prevention institute under the lead of the China CDC. It is the direction center for national infectious disease control and prevention. Its main functions are to: conduct surveillance on infectious diseases; collect, analyze and notify the CDC about the disease infections; respond to severe infectious diseases, epidemics and pandemics; emergent diseases and other emergencies.

Beijing Temple of Heaven Biological Products Co., Ltd. – specializes in marketing modern hepatitis B vaccines. The Company has a history of technology innovation; originally through advanced equipment imports. Presently all of its products and manufacturing facilities are GMP certified through the SFDA.

INCOME STATEMENT SUMMARY

Address: No. 39 Shangdi Xi Road, Haidian District, Beijing, China
Telephone: +86-10-6296-3661
CEO: Weidong Yin
Web Site: http://www.sinovac.com
State or other jurisdiction of incorporation or organization: Antigua, West Indies
Transfer Agent: Pacific Stock Transfer
Contact: Sinovac: Helen G. Yang, Tel: +86-10-8289-0088 x9871, Fax: +86-10-6296-6910, Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it . Investors: Amy Glynn/Sara Pellegrino, The Ruth Group, Tel: +1-646-536-7023/7002, Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it This e-mail address is being protected from spambots. You need JavaScript enabled to view it

EXECUTIVE TEAM

CEO: Weidong Yin

Mr. Yin is the President and CEO of Sinovac. He is also one of founders of Tangshan Yian and Sinovac Biotech Co., Ltd. He has been dedicated to hepatitis research for over 20 years starting as a doctor on epidemiology in Tangshan CDC (Hebei Province). He is credited with developing the intellectual property rights that led to the development of Sinovac’s Hepatitis A Vaccine. Mr. Yin has been appointed to be the principal investigator by the Chinese Ministry of Science and echnology for many key governmental R&D programs such as “Inactivated Hepatitis A Vaccine R&D”, “Inactivated SARS Vaccine R&D” and “New Human Influenza Vaccine (H5N1) R&D”. Mr. Yin is instrumental in shaping the Chinese Ministry of Public Health’s policy for prioritizing hepatitis as one of primary diseases to be negated by the country in the next five years.
Dr Yin also serves some public obligations. He is the member of Chinese Foundation for Hepatitis Prevention and Control. He is academic consultant to various Chinese governmental organizations.
Education: Dr Yin obtained his Medical Degree from the Tangshan Medical School in Hebei Province, PRC, pursued advanced study in Virology from the China Institute of Preventive Medical Science and obtained a Master Degree in Business Administration from the National University of Singapore.

Vice General Manager: Jiansan Zhang

Vice General Manager of Sinovac Biotech Co., Ltd.
---- In charge of Production Dept., Engineering Dept., Development Dept., and Quality Assurance Dept.; Deputy General Manager of Tangshan Yian Biological Engineering Co., Ltd.
---- In charge of P3 Lab;
Mr. Zhang has had sophisticated training courses on Biological product manufacturing management and quality control in Holland and received training on biological product manufacturing management and quality control at Merck. He fully understands European GMP standards, which was used into manufacturing workshop construction of inactivated hepatitis A vaccine and split flu vaccine, which guides the production management and quality control of Sinovac to meet international standards.
Previously he was Production manager & Senior Manager of Shenzhen Kangtai Biological Product Co., Ltd.; Vice General Manager of Shenzhen Guangxin Biological Product Co., Ltd. Consultant of Tangshan Yian Biological Engineering Co., Ltd.; Production manager of Shenzhen Kangtai iological Product Co., Ltd.; Vaccine researcher in Wuhan Biological Institute.
Education: EMBA from Tsinghua University, Bachelor in Medical Treatment from Sun Yat-sen University of Medical Sciences, Guangzhou, PRC China. Sun Yat-sen University of Medical Sciences, Bachelor in Medical Treatment;

Vice General Manager of Sinovac Biotech Co., Ltd., Ms Nan Wang

---- In charge of Business Development Dept. and Clinical Research Dept.
Ms. Wang has over 10 years of experience in the field of business development, project research and registration management,. working with China Bioway Biotech Group and Shenzhen Kexing Biological Product Co., Ltd. She has conducted studies on development strategy of biological enterprises. And at the same time she knows well about government policy relating to drug R&D and registration. She also holds very good relationship with related government officials.
Previously she was: Researcher in Live Science College of Peking University; China Bioway Biotech Group; Shenzhen Kexing Biological Product Co., Ltd.
Education: University of International Business and Economics, Master in Enterprise Management;
Peking University, Bachelor of Science in Biology; Gain Diploma in Financial Management in the course of ACCA organized in China

Vice President Mr. Changju Fu

--- In charge of Sales Dept, Marketing Dept, and Business Dept;

He has been the Sales Director of Changchun Changsheng Biological Product Co., Ltd. for 11 years in charge of vaccine marketing with a strong focus on Hepatitis A. He was appointed subsequently as the Vice President of Shenzhen Shukang Biological Products Co. Ltd. responsible for marketing and sales of vaccines and blood products. Since Sinovac’s incorporation, he contributed to building up the company’s sales team and network and responsible for the sale of Sinovac vaccines.
Previously he was: Assistant to Director of Blood research section of Institute of Changchun Biological Products, Ministry of Public Health, P.R. China; Sales Manager of Changchun Changsheng Industrial Co., Ltd.; Vice General Manager of Shenzhen Shukang Biology Co., Ltd.
Education: Graduated from Norman Bethune University of Medical Sciences.

Senior Manager, Ms. Xuejie Gong

She is a Pharmaceutical engineer. And she gained certified Professional Pharmacist in 1995. She has the experience of vaccine R&D for over 10 years. She used to work in quality assurance department of Tangshan Yian. She dedicated to the R&D of Hepatitis A vaccine and Hepatitis A&B vaccine. She is a professional in establishing the method of quality control, quality assurance, clinical trial of the vaccine and the registration for the new bio-products. After that, she also participated into the establishment of GMP administrative system of inactivated hepatitis A vaccine. And she is in charge of the registration for split flu vaccine development by Sinovac. She was certified to be senior engineer in late 2002. Currently she is the assistant to CEO. And she is in charge of QA dept. and QC dept.
Education Background: Shen Yang Pharmaceuticals College, bachelor of chemical pharmaceuticals; Training course on GMP investigator for vaccine organized by WHO.

Senior Manager, Manager of Human Resource Department, Wang Jingning

Working Experience:
2005 – now Sinovac Biotech Ltd. Senior Manager, Manager of Human Resource Department, Assistant to CEO

2001 – 2005 Sinovac Biotech Ltd. Manager of Human Resource Department
1998 – 2001 Tangshan Yian Biological Engineering Co., Ltd. Manager of Administration and Human Resource
1992 – 1998 Tangshan Biomedical Technology Development Co., Ltd. Administration Manager
Education: 1998 – 2001 RINMIN UNIVERSITY OF CHINA Master of Industrial Economics; 1985 – 1989 YANSHAN UNIVERSITY Bachelor in forge technique and equipment.

BOARD OF DIRECTORS

Mr. Weidong Yin has been the President, CEO, Secretary and a Director of the Company since September 24, 2003. Mr. Yin is also the General Manager of the Company’s subsidiary, Sinovac Biotech Co., Ltd. Mr. Weidong Yin, has been dedicated to hepatitis research for over 20 years. He is credited with developing the intellectual property that led to the development of the Company’s hepatitis A vaccine. In addition, Mr. Yin has been appointed to be the principal investigator by the Chinese Ministry of Science and Technology for many key governmental R&D programs such as “Inactivated Hepatitis A vaccine R&D”, “Inactivated SARS vaccine R&D” and “New Human Influenza Vaccine (H5N1) R&D”. He obtained his Masters degree in Business Administration from the Singapore State University.

Mr. Xianping Wang (Age 47) is a director nominee and has been the President and CEO of Xinhua China Ltd. since September 2004, which is a reporting issuer and is listed on the National Association of Securities Dealers Over-the-Counter Bulletin Board having the symbol “XHUA”. He is also President of Asia-Durable (Beijing) Investments Co., Ltd. since 2002, the President of Beijing New Fortune Investment Co., Ltd. from 1997-2002, and General Manager of Beijing Fuhua Constructions and Development Co., Ltd. from 1992-1997. Mr. Wang has obtained two university degrees, one was an Engineer Bachelor Degree from Navy Engineering Institute, and the other one was an Economy Master Degree from Tsinghua University. After graduation from university, Mr. Wang dedicated diversity industries, such as bio-medicine, healthy industry, construction projects, investment consultation and real estate development as well as other related industries. Since 1993, he has participated in varied real estate investment projects in China, managing the development of Fuhua Mansion, Meihui Mansion and Jinhua Garden, including others, with a total marketable area of 600,000 square meters.

Ms. Cathy Mok Chup Hung (“Mok”) (age 48) is a director nominee and is currently the Financial Controller of Zero Spot Laundry Service Private Limited where she is responsible for the financial affairs of that company and also leads the human resource management function. Prior to joining Zero Spot Laundry Service Private Limited, Mok had more than 28 years of banking experience. Mok joined Bank of China, Singapore Branch in January 2002. During that period, she lead the Internal Audit and Treasury Settlements functions. Mok was also a member of the bank’s Assets and Liabilities Management Committee, Prevention of Money Laundering Committee and Business Continuity Management Committee. Prior to joining Bank of China, Mok began her career with The Kwangtung Provincial Bank Singapore Branch. During that period, she worked in the retail banking division. Mok was also responsible for setting up the Kwangtung Provincial Bank’s Treasury Department. From 1992 to 2001, being the senior management member of the bank, she had oversight responsibilities in accounting, treasury settlements, human resource management and credit management functions. In addition, Mok was a member of Kwangtung Provincial Bank’s Credit Committee and Prevention of Money Laundering Committee. Mok holds a Master of Business Administration from the National University of Singapore.

Mr. Simon Anderson has been a Director of the Company since July 23, 2004. Mr. Anderson has been a partner and Vice President of MCSI Consulting Services Inc. from 1996 to present. Mr. Anderson is a Chartered Accountant and a Chartered Business Valuator and from 1994 to 1996 was a partner with BDO Dunwoody, an international accounting and consulting firm, where he specialized in mergers, acquisitions and valuations. Mr. Anderson was admitted as a member of the Institute of Chartered Accountants in British Columbia in 1986. He has also been a member of the Canadian Institute of Charter Business Valuators since 1990. In addition, Mr. Anderson is a director and/or Chief Financial Officer of four other public companies.

Mr. Lo Yuk Lam (age 58) is a director nominee and is presently the Vice President of PerkinElmer Life and Analytical Sciences, Pacific Rim, the Chairman of the Chinese Manufacturers’ Association of Hong Kong – Industry Technology Committee, and the Director of the Chinese Manufacturers’ Association of Hong Kong. Professor Lo was the Chairman of the Innovation and Technology Fund (Biotechnology Projects) Vetting Committee, HKSAR, and of the Biotechnology Committee, Industry & Technology Development Council, HKSAR. He was also the Director of the Hong Kong Applied R&D Fund Co., Ltd., HKSAR. Prof. Lo was heavily involved in several committees of the Industry Department of the HKSAR Government. Prof. Lo has been awarded the Honorary Fellow by the Hong Kong University of Science and Technology and the Honorary Chairman of the City University Committee of Co-operative Education Centre. Prof. Lo has extensively served the societies of Greater China. He is currently a Member of the Advisory Committee of the World Trade Centre Association (Hong Kong), an Adjunct Professor of the Chinese University of Hong Kong, the Special Advisor of the Hong Kong University of Science & Technology (HKUST), a Committee Member of the Biotechnology Research Institute (BRI) of HKUST, and a Member of the Advisory Committee of the City University of Hong Kong and the Hong Kong Polytechnic University. In Mainland China, Prof. Lo is the Consultant of the Economic Bureau, Changchun, a Member of the Advisory Committee of the Shenzhen Municipal Science and Technology Bureau, the Honorary Consultant of the Beijing Medical University, the Honorary Professor of Chengdu University of TCM and the Visiting Professor of the Xiamen University China and the Shanghai Jiao Tong University.

IPOdesktop (ID) SAFE HARBOR STATEMENT: Statements contained in this document, including those pertaining to estimates and related plans, potential mergers and acquisitions, estimates, growth, establishing new markets, expansion into new markets and related plans other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. ID provides no assurance as to the subject company's plans or ability to effect any planned and/or proposed actions. ID has no first-hand knowledge of management and therefore cannot comment on its capabilities, intent, resources, nor experience and makes no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company or its agent and related sources believed by ID to be reliable, but ID provides no assurance, and none is given, as to the accuracy and completeness of this information.

DISCLAIMER: The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. Past performance is no guarantee of future results. This report is a paid advertisement and is for information purposes only and should not be used as the basis for any investment decision. ID has been compensated up twenty five hundred dollars for preparation and posting of this report and other advertising services. This constitutes a conflict of interest as to ID’s ability to remain objective in its communication regarding the subject company. Analysts, principals, associates and employees of ID do not own or trade equities under coverage. For detailed disclosure as required by Rule 17b of the Securities Act of 1933/1934 contact IPOdesktop, 11693 San Vicente Blvd., #350, Los Angeles, CA 90049. ID is not an investment advisor and this report is not investment advice. This information is neither a solicitation to buy nor an offer to sell securities but is a paid advertisement. Information contained herein contains forward-looking statements and is subject to significant risks and uncertainties, which will affect the results. The opinions contained herein reflect our current judgment and are subject to change without notice. We encourage our readers to invest carefully and read the investor information available at the web sites of the U.S. Securities and Exchange Commission (SEC) at http://www.sec.gov and the National Association of Securities Dealers (NASD) at http://www.nasd.com. The NASD has published information on how to invest carefully at its web site. Readers can review all public filings by companies at the SEC's EDGAR page.

---

If you like us, spread the word to the fellow investors on your favorite Social Bookmarking websites